PMID- 37256314
OWN - NLM
STAT- MEDLINE
DCOM- 20230717
LR  - 20230718
IS  - 1432-1955 (Electronic)
IS  - 0932-0113 (Linking)
VI  - 122
IP  - 8
DP  - 2023 Aug
TI  - Vitamin C-rich juice co-administration with artemether-lumefantrine ameliorates 
      oxido-inflammatory responses in Plasmodium berghei-infected mice.
PG  - 1841-1850
LID - 10.1007/s00436-023-07885-5 [doi]
AB  - This study investigated the effects of co-administration of a commercial juice 
      rich in vitamin C (Vit C) on the antimalarial efficacy of artemether-lumefantrine 
      (AL) in Plasmodium berghei-infected mice. Fifty Balb/c mice were infected with 
      Plasmodium berghei NK65 strain from a donor mouse. Parasitemia was established 
      after 72 h. Animals were grouped into 6 (n = 10) and treated daily for 3 days 
      with normal saline, chloroquine, artemether-lumefantrine (AL), AL plus 50% 
      commercial juice (CJ), and AL plus 50% Vit C supplementation in drinks ad 
      libitum, respectively. Body weight, parasitemia levels, and mean survival time 
      were determined. Tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), 
      nitrite, malondialdehyde, reduced glutathione (GSH), catalase, and superoxide 
      dismutase (SOD) were determined in the serum and liver tissues. Spleen 
      histopathological changes were determined by H&E staining. Parasitemia was 
      cleared by administration of AL and was not affected by Vit C and CJ 
      supplementation. Vit C significantly prevented body weight reduction in 
      AL-treated mice. CJ and Vit C supplementation to AL-treated mice significantly 
      improved survival proportion compared with AL alone animals. Vit C and CJ 
      supplementation significantly improved reduction of TNF-alpha, IL-6, and 
      malondialdehyde, and increased GSH, CAT, and SOD in AL-treated mice. Spleen cell 
      degeneration and presence of malaria pigment were reduced in AL-treated animals. 
      The results suggest that ad libitum co-administration of commercial juice and 
      vitamin C with artemether-lumefantrine does not impair its antimalarial efficacy 
      but rather improved antioxidant and anti-inflammatory effects in mice.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Ajayi, Abayomi M
AU  - Ajayi AM
AD  - Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, 
      University of Ibadan, Ibadan, Oyo-State, Nigeria. yomexj@yahoo.com.
FAU - Adebanjo, Iyanuoluwa M
AU  - Adebanjo IM
AD  - Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, 
      University of Ibadan, Ibadan, Oyo-State, Nigeria.
FAU - Ademowo, Olusegun G
AU  - Ademowo OG
AD  - Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, 
      University of Ibadan, Ibadan, Oyo-State, Nigeria.
AD  - Institute of Advanced Medical Research and Training (IAMRAT), College of 
      Medicine, University of Ibadan, Ibadan, Oyo-State, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20230531
PL  - Germany
TA  - Parasitol Res
JT  - Parasitology research
JID - 8703571
RN  - 0 (Antimalarials)
RN  - 0 (Artemether, Lumefantrine Drug Combination)
RN  - C7D6T3H22J (Artemether)
RN  - PQ6CK8PD0R (Ascorbic Acid)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - 4Y8F71G49Q (Malondialdehyde)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Antimalarials/therapeutic use/pharmacology
MH  - Artemether, Lumefantrine Drug Combination/pharmacology/therapeutic use
MH  - Plasmodium berghei
MH  - Artemether/pharmacology/therapeutic use
MH  - *Malaria/drug therapy/pathology
MH  - Ascorbic Acid/pharmacology
MH  - Parasitemia/drug therapy
MH  - Interleukin-6
MH  - Tumor Necrosis Factor-alpha
MH  - Superoxide Dismutase
MH  - Malondialdehyde
OTO - NOTNLM
OT  - Antioxidants
OT  - Artemether-lumefantrine
OT  - Commercial juice
OT  - Plasmodium berghei
OT  - Vitamin C
EDAT- 2023/05/31 13:12
MHDA- 2023/07/17 06:42
CRDT- 2023/05/31 11:04
PHST- 2023/01/08 00:00 [received]
PHST- 2023/05/17 00:00 [accepted]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/05/31 13:12 [pubmed]
PHST- 2023/05/31 11:04 [entrez]
AID - 10.1007/s00436-023-07885-5 [pii]
AID - 10.1007/s00436-023-07885-5 [doi]
PST - ppublish
SO  - Parasitol Res. 2023 Aug;122(8):1841-1850. doi: 10.1007/s00436-023-07885-5. Epub 
      2023 May 31.